ClinicalTrials.gg
RecruitingNCT06479616Updated Oct 26, 2026

A Long-term Follow-up Study in Participants Who Received CS-101

An interventional study of CS-101 in Beta-Thalassemia, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Children's Hospital of Fudan University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
23rd of 34
5 · median 10
Started
2024
with 10 others
No phase
13 of 44
4 open now
Primary completion
2026-12
later than 10 of 24 live
Registered
37th of 44
by date
Lead sponsor
2 of 44
Children's Hospital of Fudan University

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 23rd largest by planned enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 13 with no phase, reaches primary completion later than 10 of the 24 other live ones, and was the 37th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)

Read the detailed description

This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189) .

Subjects in the CS-101-03 study will be entered into long-term follow-up of this study up to 2 years post-infusion at the completion of the last (6-month) follow-up visit after treatment with CS-101 Injection.

03

Conditions studied

  • Beta-Thalassemia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants (or his or her legally appointed and authorized representative or guardian) must sign and date form (ICF) and, where applicable, an assent form
  • Participants must have received CS-101 infusion in last IIT study

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    long term follow up

    All participants who complete CS-101-03(NCT0606518) studie after CS-101 infusion will be asked to participate in this long-term follow-up study.

    Genetic: CS-101

Interventions

  • GeneticCS-101

    Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

06

What researchers measure

Primary outcomes

  1. Frequency and severity of SAEs and CS-101 related AES as assessed by CTCAE v5.0

    CommonTerminology Criteria for Adverse Events(CTCAE)has 5 levels of AE determination, increasing in severity as the level increases

    Time frame: Signing of informed consent up to 2 years post CS-101 infusion

  2. Occurrence of all-cause death

    Time frame: Signing of informed consent up to 2 years post CS-101 infusion

  3. New malignancies and hematologic disorders

    Based on ICD-11

    Time frame: Signing of informed consent up to 2 years post CS-101 infusion

  4. Occurrence of achieving transfusion independence for at least 12 consecutive months

    Time frame: From 3 months after last RBC transfusion up to 2 years post CS-101 infusion

Secondary outcomes

  1. Change in fetal hemoglobin(HbF) concentration over time

    Time frame: up to 2 years post-CS-101 infusion

  2. Change in total hemoglobin(Hb) concentration over time

    Time frame: up to 2 years post-CS-101 infusion

  3. Chimerism level in Peripheral blood and bone marrow Proportion of alleles with intended genetic modification in peripheral blood leukocytes and bone marrow over time

    Proportion of alleles with intended genetic modification in peripheral blood leukocytes and bone marrow over time

    Time frame: up to 2 years post-CS-101 infusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 28, 2024
StartActual
Jun 18, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06479616
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Jun 18, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Xiaowen Zhai, M.D.
Contact
zhaixiaowendy@163.com
+86-021-64931126
Zifeng Li, M.S.
Contact
zfli18@fudan.edu.cn
+86-13920704768
Xiaowen Zhai, M.D.
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion